TRIDENT

• Consortium Members and Industry Partners

Consortium members

TRIDENT is a multi-center academic–industry research consortium bringing together leading nephrologists, renal pathologists, translational scientists, and biopharmaceutical partners committed to advancing precision medicine for diabetic kidney disease. Consortium participation has evolved as the study has progressed through different phases, with a focused group of academic sites currently leading enrollment, data generation, and analysis.

Academic Consortium Sites

Active Participating Sites 

The following institutions are actively engaged in TRIDENT through participant enrollment, data contribution, and/or ongoing scientific analyses:

• University of Pennsylvania — Gaia Coppock, MD

• Ohio State University — Brad Rovin, MD

• University of North Carolina at Chapel Hill — Amy Mottl, MD

Active Analysis Sites (Enrollment Complete)

The following institutions remain actively involved in data contribution, analysis, and scientific leadership, with enrollment now complete:

• Albert Einstein College of Medicine / Montefiore Medical Center — Michael Ross, MD

• Icahn School of Medicine at Mount Sinai— Kirk Campbell, Michael Ross, MD

• Northwestern University — Tamara Isakova, MD

• Stanford University — Richard Lafayette, MD

• Oregon Health & Science University — Rupali Avasare, MD

• University of New Mexico — Christos Argyropoulos, MD

• University of Virginia — Julia Scialla, MD

• Yale University — Randy Luciano, MD

Contributing and Legacy Sites

The following institutions and investigators made important contributions to earlier phases of TRIDENT study design, enrollment, and data generation. Their foundational work helped establish the TRIDENT platform and consortium infrastructure:

• UT Health San Antonio— Shweta Bansal, MD

• University of Miami — Alessia Fornoni, MD, PhD

• University of Michigan — Matthias Kretzler, MD

• University of Arizona — Frank Brosius, MD

• Columbia University — Pietro Canetta, MD

• Lehigh Valley Health Network — Nelson Kopyt, MD

• MetroHealth Medical Center — Jeff Schelling, MD

• Baylor Scott & White Research Institute — Harold Szerlip, MD

• Georgia Nephrology — James Thumlin, MD

Industry Partners

TRIDENT collaborates with leading biopharmaceutical companies committed to advancing the understanding and treatment of diabetic kidney disease. These partnerships support translational insight, biomarker development, and alignment with therapeutic innovation while preserving academic independence and scientific integrity.

Current and past industry collaborators include:

• Boehringer Ingelheim

• Novo Nordisk

• AstraZeneca

• Genentech

• GlaxoSmithKline

• Regeneron

• Gilead Sciences